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Abstract
Epstein-Barr virus (EBV) is an oncogenic virus that is associated with the pathogenesis of several human lymphoid
malignancies, including Hodgkin’s lymphoma. Infection of normal resting B cells with EBV results in activation to
lymphoblasts that are phenotypically similar to those generated by physiological stimulation with CD40L plus IL-4. One
important difference is that infection leads to the establishment of permanently growing lymphoblastoid cell lines, whereas
CD40L/IL-4 blasts have finite proliferation lifespans. To identify early events which might later determine why EBV infected
blasts go on to establish transformed cell lines, we performed global transcriptome analyses on resting B cells and on EBV
and CD40L/IL-4 blasts after 7 days culture. As anticipated there was considerable overlap in the transcriptomes of the two
types of lymphoblasts when compared to the original resting B cells, reflecting common changes associated with
lymphocyte activation and proliferation. Of interest to us was a subset of 255 genes that were differentially expressed
between EBV and CD40L/IL-4 blasts. Genes which were more highly expressed in EBV blasts were substantially and
significantly enriched for a set of interferon-stimulated genes which on further in silico analyses were found to be repressed
by IL-4 in other cell contexts and to be up-regulated in micro-dissected malignant cells from Hodgkin’s lymphoma biopsies
when compared to their normal germinal center cell counterparts. We hypothesized that EBV and IL-4 were targeting and
discordantly regulating a common set of genes. This was supported experimentally in our B cell model where IL-4
stimulation partially reversed transcriptional changes which follow EBV infection and it impaired the efficiency of EBV-
induced B cell transformation. Taken together, these data suggest that the discordant regulation of interferon and IL-4
pathway genes by EBV that occurs early following infection of B cells has relevance to the development or maintenance of
an EBV-associated malignancy.
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Introduction
The normal process of B lymphocyte activation in response to
encountering antigen involves complex cellular and cytokine
interactions in the germinal centers of peripheral lymphoid tissues,
leading to clonal expansion followed by differentiation into effector
or memory cells. Some aspects of this self -limiting proliferation
can be replicated in vitro through combinations of signals; one
widely-used method of generating B cell blast involves co-
stimulation with CD40L and IL-4. In this context, the pleiotropic
IL-4 cytokine acts as an essential proliferation signal [1,2],
although its effects on malignant cells can be anti-proliferative
and pro-apoptotic [3–10].
In contrast to CD40L/IL4 B blasts, which usually have finite
proliferative lifespans [11], experimental infection of resting B cells
with Epstein-Barr virus (EBV) in culture regularly results in the
establishment of lymphoblastoid cell lines (LCL) with indefinite
proliferation potential [12,13]. EBV is therefore a potent
transforming agent, and it is unsurprising that the virus is
aetiologically associated with lymphoproliferative diseases, includ-
ing the B cell tumors: Burkitt’s lymphoma, Hodgkin’s lymphoma
(HL), diffuse large B cell lymphoma of the elderly, and post-
transplant lymphoproliferative disease [14].
EBV is a herpesvirus with a DNA genome containing in the
region of 90 genes [15]. However, only 9 or 10 viral proteins are
regularly expressed in LCLs, which generally display a non-
productive or ‘latent’ infection [16]. Of the transformation-
associated latent viral proteins, at least one, LMP1, is oncogenic
by classical criteria; its ectopic expression in model rodent
fibroblast lines leads to cellular transformation in vitro and
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acquisition of a tumorigenic phenotype in vivo [17,18]. Although
showing no overall sequence homology with any cellular proteins,
LMP1 functions as a constitutively-active member of the tumor
necrosis factor receptor family which includes CD40 [19]. LMP2A
is a trans-membrane signaling protein that behaves as a
constitutively active functional homologue of the B cell receptor
[20,21]. The remaining transformation-associated proteins are
mostly nuclear proteins (EBNA1, EBNA2, EBNA3A, EBNA3B,
EBNA3C and EBNA-LP), which again show no significant
homology to cellular proteins although their effects on regulation
of cellular transcription and signaling pathways are well-studied
[15]. Transformation of B cells by EBV cannot be attributed to a
single viral oncogene. Rather, the cooperative functions of
multiple viral genes are required, as demonstrated by studies with
recombinant EBVs, which show that deletion of any one of
EBNA1, EBNA2, EBNA3A, EBNA3C or LMP1 genes will abolish
or substantially reduce transforming ability [22,23].
Whilst the functions of the transformation-associated EBV genes
have been the subject of considerable research over the last 2 or 3
decades, some fundamental questions remain unanswered. One of
these concerns why EBV-infected normal B cells are transformed
into blasts that grow indefinitely, whilst B cell blasts generated, for
example by continuous stimulation with CD40L and IL-4, have
finite proliferative potential lasting a few weeks. This is an
important question as it impacts on our understanding of the role
of EBV in the pathogenesis of B cell tumors.
As part of a strategy to address this question, we compared the
global transcriptomes of these two types of B blasts at 7 days after
virus infection or CD40L/IL-4 stimulation of normal peripheral
blood B lymphocytes. Consistent with published data indicating
the phenotypic similarities of EBV- and mitogen-induced B blasts
[24], we found that there was considerable overlap in their
transcriptomes and that mRNA changes relative to the original
resting B cells largely reflected common changes associated with
lymphocyte activation and cell proliferation. Of greater interest to
us was the subset of genes that was differentially expressed between
EBV and CD40L/IL-4 blasts. Analysis of this latter set of genes
identified an intriguing discordance of EBV and IL-4 mediated
transcriptional regulation that is functionally relevant to EBV-
induced cellular transformation.
Materials and Methods
Ethics statement
Buffy coats or apheresis cones, obtained from the National
Health Service Blood and Transplant service (NHSBT) in
Birmingham, were used as the source of peripheral blood for this
study. Healthy blood donors were recruited according to NHSBT
standard procedures, which included obtaining full consent to
allow use of donations for our experiments.
Isolation of B cells and generation of B blasts
Peripheral blood mononuclear cells (PBMCs) were isolated from
buffy coat samples or apheresis cones, obtained from NHSBT, by
discontinuous gradient centrifugation over Lymphoprep separa-
tion medium (Robbins Scientific). CD19+ B cells were isolated
using magnetic CD19 Dynabeads (Dynal, Invitrogen) according to
the manufacturer’s recommendations. Briefly, 26106 PBMCs and
107 Dynabeads per ml were co-incubated at 4uC for 30 min before
isolation of B cells with bound Dynabeads by exposure to a
magnet. The isolated B cells were washed 5 times before removal
of the beads with DETACHaBEADH CD19 (Dynal, Invitrogen).
Virus for infection experiments was obtained from 293 cells
containing the 2089 recombinant EBV genome [25] and virus
titration was carried out using real-time quantitative polymerase
chain-reaction (qPCR) as previously described [26]. EBV infection
of isolated CD19+ B cells was performed by incubation of cells at
37uC for 2 h with EBV at 100 m.o.i. (multiplicity of infection)
before washing away excess virus and seeding at 26106 cells/ml in
fresh medium (RPMI-1640 with 10% fetal calf serum) and
culturing at 37uC. Parallel cultures of mitogen-stimulated B blasts
were set up in cell culture medium containing 50 ng/ml of soluble
trimeric human recombinant megaCD40L (Alexis Biochemicals)
and 50 ng/ml IL-4 (ProSpec-Tany).
EBV transformation assay
EBV transformation assays were carried out as described
elsewhere [26], using 96-well plates with a fixed number of 103 B
cells/well and a range of virus doses (0.2–100 m.o.i.). Wells were
examined for transformed colonies after 6 weeks culture.
Microarray experiments
The mirVanaTMPARISTM kit (Applied Biosystems) was used to
extract total RNA from resting B cells isolated from PBMCs, and
from B cells stimulated with CD40L and IL-4 for 7 days or
infected with EBV at a m.o.i. of 100 and harvested 7 days post-
infection. RNA quality was monitored using a Bioanalyzer 2100
(Agilent, Stockport UK) then prepared for transcriptional profiling
on GeneChip Human Exon 1.0 ST Arrays (Affymetrix, High
Wycombe UK) according to the manufacturer’s recommenda-
tions. Briefly, 100 ng of RNA was used to transcribe single
stranded cDNA using oligo dT primers. A second strand was then
synthesised and the double stranded cDNA purified. This double
stranded cDNA was used as a template to generate fluorescently
labelled cRNA by in vitro transcription, which was purified and
fragmented before being hybridised to the microarray chip.
Scanned images of microarray chips were analysed using the
Affymetrix GeneChip Command Console. Gene level analysis of
the array data was performed using Affymetrix Expression
Console with the default settings of ‘‘Core: RMA-Sketch’’.
Differentially expressed genes were identified using LIMMA [27]
with a cut-off p value of 0.01. Array annotation was based on
Affymetrix NetAffx annotation release 32 (June, 2011) and gene
symbols were updated according to NCBI gene database
downloaded on August 26, 2011. The primary data are available
from GEO under series accession number GSE45829 (http://
www.ncbi.nlm.nih.gov/geo/).
DAVID gene ontology analysis
Lists of probe-sets from the GeneChip Human Exon 1.0 ST
Arrays were generated according to selection criteria indicated in
the results section and were submitted to DAVID gene ontology
analysis (http://david.abcc.ncifcrf.gov/home.jsp) [28,29], select-
ing the PANTHER_BP_ALL chart option. The probe-lists used
and the complete results of these analyses are available in Data-
File S1.
Quantitative reverse-transcriptase qPCR (RT-qPCR)
TaqmanH custom array cards (Applied Biosystems) were
designed to allow simultaneous quantitation of 8 RNA samples
per microfluidics card with 48 unique assays. For each sample
50 ng total RNA was reverse-transcribed and loaded and run
according to the manufacturer’s instructions in a 7900HT PCR
machine with a Low Density Array upgrade (Applied Biosystems).
Data was analysed using the SDS2.2.2 software (Applied
Biosystems) according to manufacturer’s instructions using the
EBV Targeting ISG/IL-4 Pathways for Transformation
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ddCt method [30] and exported into Microsoft Excel for further
analysis.
Individual RT-qPCR assays for cellular transcripts (see Table
S1) were purchased from Applied Biosystems, and used according
to the manufacturer’s recommendations; cDNA was obtained by
reverse-transcribing 20–400 ng total RNA with random hexamer
primers.
Results
Comparison of the transcriptomes of EBV- and mitogen-
induced B blasts
Gene expression profiling identified 4197 and 1666 genes as
significantly altered following EBV infection and CD40L/IL-4
stimulation, respectively (LIMMA; p,0.01, FC.1.5). As expect-
ed, there was a significant and substantial over-lap between these
transcriptional profiles with 1410 genes altered by both EBV and
mitogen (OR=22.6, x21df = 2506, p,0.0001; Figure 1A and
Table 1A). Of these overlapping 1410 significant transcriptional
changes, 99.6% were altered in the same direction by EBV and by
CD40L/IL-4; and only 6 genes were significantly up-regulated by
EBV and significantly down-regulated by CD40L/IL-4, or vice
versa (Figures 1B, 1C and Table 1). The six discordantly regulated
genes were ZNF487P and PIM2 ( up-regulated by EBV but down-
regulated by CD40L/IL-4), and SPINT2, SIGLEC10, TSPAN33
and DUSP6 (down-regulated by EBV but up-regulated by
CD40L/IL-4).
So far we have only compared gene expression measured at day
7 with that observed in the initial resting B cells. To characterize
more fully the transcriptional differences which follow EBV or
CD40L/IL4 stimulation, we next directly compared the tran-
scriptomes of the two types of blast at day 7. In this way, we
identified 255 genes which were differently expressed between
EBV blasts and CD40L/IL-4 blasts (p,0.01, FC.2), of which
138 were expressed higher in EBV blasts than in CD40L/IL-4
blasts, and 117 were expressed lower in EBV blasts than in
CD40L/IL-4 blasts (Data-File S2). Independent quantitative RT-
qPCR assays for 40 of these differentially expressed genes
confirmed .2 FC in every case (Table S1).
Ontological profiling of the transcriptomes of EBV- and
mitogen-induced B blasts
Not surprisingly, given the extent of the overlap between these
datasets, the ontological profiles of genes transcriptionally changed
by EBV and CD40L/IL-4 were very similar (Data-File S1), with
both transcriptomes being enriched for ontological functions
linked to DNA replication, cell cycle, metabolic pathways, and
immune responses.
The set of genes differentially expressed between EBV blasts
and CD40L/IL-4 blasts was enriched for gene functions linked to
the immune response, most notably the interferon responses and
cytokine/chemokine signaling pathways (Table 2). These initial
analyses suggest that EBV and CD40L/IL-4 both concordantly
and discordantly regulate different sets of immune response genes.
To investigate these associations further, our analyses were
extended to include comparisons with published array datasets
in which interferon (IFN) and other cytokine responses were
specifically examined.
Interferon responses to EBV infection or CD40L/IL-4
stimulation
We first compared the transcriptional profiles of EBV and
CD40L/IL-4 stimulated blasts with a list of type-I IFN-stimulated
genes (ISGs) provided by Schoggins et al [31]; these authors had
identified from a meta-analysis of published arrays 389 ISGs, of
which 370 were also listed on the HuExon ST 1.0 array platform
used in our experiments. Confirming the impression left by
ontological profiling, this more detailed comparison (Table 3A)
showed that genes up-regulated by EBV were significantly
enriched for ISG (OR=8.5, x21df = 250, p,0.0001) as were those
up-regulated by CD40L/IL-4, albeit to a lesser extent (OR=3.0,
x21df = 25.8, p,0.0001). We also confirmed that the genes
differentially expressed between EBV blasts and CD40L/IL-4
blasts at day 7 were substantially and significantly enriched for
ISGs (Table 3A); this association was strongest for those genes
expressed higher in EBV blasts than in CD40L/IL-4 blasts
(OR=16.8, x21df = 339, p,0.0001).
Similar but more substantial correlations were obtained when
comparing the transcriptional profiles of EBV and CD40L/IL-4
stimulated blasts with a set of IRF-1 regulated genes identified
experimentally by Schoggins et al [31] (Table 3B). Genes up-
regulated by EBV compared with resting B cells were substantially
and significantly enriched for IRF-1 regulated genes (OR=24.3,
x21df = 494, p,0.0001), as were those expressed more highly in
EBV blasts than in CD40L/IL-4 blasts (OR=44.8, x21df = 682,
p,0.0001).
Whilst IRF-1 is an important mediator of type-I IFN responses,
expression of IRF-1 transcripts themselves was only slightly and
non-significantly increased at 7 days after EBV infection (FC=1.3;
p = 0.106) and non-significantly decreased in response to CD40L/
IL-4 (FC=1.4; p= 0.141).
IL-4 signaling pathways and EBV-induced interferon
responses
Given that IFNs and cytokines such as IL-4 cross-regulate each
other’s signaling in different cell types, including B cells [32–35],
our analyses were extended to include comparisons with a series of
array experiments by Elo et al [35] examining the effect of IL-4 on
IL-2 stimulated CD4 T cells.
We first confirmed a relationship between IFN and IL-4
pathways using the datasets generated by Schoggins et al [31] and
Elo et al [35]. IL-4 transcriptional targets were enriched for both
ISGs and IRF-1 regulated genes (Figure 2, Table 4). Most notably,
as shown in Table 4B, genes that were down-regulated by IL-4
were substantially and significantly enriched both for ISGs
(OR=19.6, x21df = 998, p,0.0001) and for IRF-1 induced genes
(OR=57.7, x21df = 1271, p,0.0001).
In light of this, and considering the relationship between subsets
of EBV-regulated genes and ISGs and IRF-1 targets (Table 3), it
was perhaps unsurprising that genes up-regulated by EBV were
enriched for genes down-regulated by IL-4 (OR=7.7, x21df = 244,
p,0.0001; Table 4B). In addition, genes that were expressed at
significantly greater levels in EBV blasts than in CD40L/IL-4
blasts showed an even greater enrichment of genes down-regulated
by IL-4 (OR=19.0, x21df = 441, p,0.0001; Table 4B).
This link between IL-4 signaling and EBV infection was
confirmed directly in our B cell model by analysis of a selection of
the genes reported by Elo et al to be down-regulated in T cells but
which we found to be up-regulated following EBV infection. The
results for six such genes (IFIT1, IFIT3, IFITM1, OAS2, IFI44
and USP18) are shown in Figure 3A. In each example, EBV
infection caused a substantial up-regulation of transcripts but the
addition of IL-4 coincident with EBV infection led to a significant
down-regulation of transcripts, albeit never to the low levels
detected in control uninfected cells with or without IL-4.
Furthermore, when examining 2 sample genes (SPINT2, DUSP6)
shown by Elo et al to be up-regulated by IL-4 in T cells but, in our
EBV Targeting ISG/IL-4 Pathways for Transformation
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B cell experiments to be down-regulated by EBV infection, we
again found that coincident IL-4 stimulation and EBV infection
attenuated the effects of EBV infection (Figure 3B).
IL-4 impairs EBV-induced B cell transformation
These analyses suggested a link between EBV-induced IFN
responses and discordant regulation of IL-4 pathway genes. To
elucidate the functional significance of this observation, we
examined what effect IL-4 itself might have on the ability of
Figure 1. Similarities in the transcriptomes of blasts induced by EBV infection or by CD40L/IL4 treatment of resting peripheral
blood B cells. Significant changes in transcript expression were identified by paired LIMMA (p,0.01; FC.1.5) and complete gene-lists are available
in Data-File S2. (A) Venn diagram indicating the overlap of the 4197 genes changed by EBV and the 1666 genes changed by CD40L/IL4, irrespective of
the direction of the change. (B) Venn diagram showing the 3519 genes that were up-regulated by EBV, and the overlap with the 1394 genes up-
regulated by CD40L/IL4 and the 272 down-regulated by CD40L/IL4. (C) Venn diagram showing the 679 genes that were down-regulated by EBV, and
the overlap with the 1394 genes up-regulated by CD40L/IL4 and the 272 down-regulated by CD40L/IL4.
doi:10.1371/journal.pone.0064868.g001
Table 1. Similarities in gene-expression changes induced by EBV and CD40L/IL4.
Comparisons between gene sets*
overlap between
gene-sets Odds Ratio Chi-Square P Value (1 df)
A. Altered by EBV (n = 4197) and: Altered by CD40L/IL4 (n = 1666) 1410 22.6 2506 ,0.0001
B. Up-regulated by EBV (n = 3519) and: Up-regulated by CD40L/IL4 (n = 1394) 1180 29.2 2837 ,0.0001
Down-regulated by CD40L/IL4 (n = 272) 2 0.028 51.4 ,0.0001
C. Down-regulated by EBV (n = 679) and: Up-regulated by CD40L/IL4 (n = 1394) 4 0.065 47.0 ,0.0001
Down-regulated by CD40L/IL4 (n = 272) 225 172 4306 ,0.0001
*Numbers in parentheses indicate the number of genes within the gene-set. Note that for one gene (ZNF487P), one probe-set was up- regulated and one was down-
regulated by EBV compared to resting B cells.
Genes altered by EBV or by CD40L/IL4 on day 7 relative to resting B cells at day 0 were determined by a paired LIMMA analysis with a significance threshold of P,0.01;
FC.1.5. The Odds Ratio (OR) and significance of the overlaps were determined using the denominator, 17311, representing the total number of unique annotated
genes on the HuExon 1.0 ST array. Complete gene-lists are available in Data-File S2.
doi:10.1371/journal.pone.0064868.t001
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Table 2. Ontology analysis of genes differentially expressed between EBV blasts and CD40L/IL-4 blasts.
Gene-sets Ontological term Hit count Fold Enrichment P Value
A. EBV?CD40L/IL-4 Interferon-mediated immunity 11 11.6 ,0.0001
Cytokine/chemokine mediated immunity 9 5.2 0.0004
B-cell- and antibody-mediated immunity 7 5.1 0.0025
Macrophage-mediated immunity 10 4.9 0.0002
Cytokine and chemokine signaling pathway 14 3.9 ,0.0001
T-cell mediated immunity 10 3.7 0.0016
Immunity and defense 53 2.8 ,0.0001
Ligand-mediated signaling 14 2.4 0.0063
B. EBV.CD40L/IL-4 Interferon-mediated immunity 11 23.3 ,0.0001
Macrophage-mediated immunity 7 7.0 0.0005
Immunity and defense 28 3.0 ,0.0001
C. EBV,CD40L/IL-4 T-cell mediated immunity 9 6.5 ,0.0001
Cytokine and chemokine signaling pathway 8 4.4 0.0021
Immunity and defense 25 2.6 ,0.0001
Cell communication 18 2.1 0.0052
Signal transduction 39 1.6 0.0021
Ontology analysis of genes differentially expressed between EBV and CD40L/IL-4 blasts by paired LIMMA (p,0.01, FC.2) was performed using the DAVID v6.7
bioinformatics resource [28,29] to identify Panther Biological Processes terms for which there was a significant enrichment of genes. The lists of probe-sets entered into
DAVID v6.7 and the complete analyses readouts are given in Data-File S1. The probe-sets analyzed were those which were: (A) differentially expressed between EBV and
CD40L/IL-4 blasts at day 7, (B) the subset of differentially expressed genes that was expressed higher in EBV blasts than in CD40L/IL-4 blasts, and (C) the subset of
differentially expressed genes that was expressed lower in EBV blasts than in CD40L/IL-4 blasts.
doi:10.1371/journal.pone.0064868.t002
Table 3. Expression of Interferon-regulated genes by EBV and CD40L/IL4 blasts.
Comparisons between gene sets*
overlap between
gene-sets
Odds
Ratio Chi-Square P Value (1 df)
A. ISGs (n = 370) and: Up-regulated by EBV (n = 370) 54 8.5 250 ,0.0001
Up- regulated by CD40L/IL4 (n = 370) 23 3.0 25.8 ,0.0001
Down-regulated by EBV (n = 370) 14 1.7 3.85 0.0497
Down- regulated by CD40L/IL4 (n = 263) 15 2.7 13.9 0.0002
Differentially expressed between EBV and
CD40L/IL4 blasts (n = 249)
41 9.5 223 ,0.0001
Higher in EBV blasts than CD40L/IL4 blasts (n = 134) 35 16.8 339 ,0.0001
Lower in EBV blasts than CD40L/IL4 blasts (n = 115) 6 2.4 4.48 0.0343
B. IRF-1 regulated genes (n = 113) and: Up-regulated by EBV (n = 370) 38 24.3 494 ,0.0001
Up- regulated by CD40L/IL4 (n = 370) 16 7.4 71.1 ,0.0001
Down-regulated by EBV (n = 370) 0 - - -
Down- regulated by CD40L/IL4 (n = 263) 0 - - -
Differentially expressed between EBV and CD40L/IL4
blasts (n = 249)
27 22.7 373 ,0.0001
Higher in EBV blasts than CD40L/IL4 blasts (n = 134) 26 44.8 682 ,0.0001
Lower in EBV blasts than CD40L/IL4 blasts (n = 115) 1 1.3 0.055 0.815
*Numbers in parentheses indicate the number of genes within the gene-set analyzed.
Comparisons were restricted to the 16420 genes present on both the HuExon 1.0 ST and the U133 plus2 Affymetrix array platforms. The size of each comparator gene-
set was selected to ensure as far as was practical that similar-sized sets were being analyzed. For example, genes up-regulated by EBV were ranked in order of FC, and
the top 370 were selected for comparison with the 370 ISGs. Complete gene-lists are available in Data-File S2. (A) Of the 389 ISGs described by Schoggins et al [31]
through meta-analysis of published arrays, 370 were present in the 16420 annotated genes common to both array platforms. (B) Of the 124 unique genes identified
experimentally by Schoggins et al [31] as being up-regulated by IRF-1, 113 were present in the 16420 annotated genes common to both array platforms.
doi:10.1371/journal.pone.0064868.t003
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Figure 2. Relationships between genes regulated by Interferon, IRF-1, and IL-4. Venn diagrams showing the overlaps of 370 ISGs and 113
IRF-1 up-regulated genes defined by Schoggins et al. [31] with IL-4-regulated genes (567 up-regulated and 452 down-regulated) identified by Elo et al
[35]. Only genes that were annotated and common to both U133 plus 2 and Human Exon 1.0 ST Affymetrix array platforms (i.e. 16420 genes) were
analysed here. Complete gene-lists are available in Data-File S2.
doi:10.1371/journal.pone.0064868.g002
Table 4. Expression of IL4-regulated genes by EBV-infected B blasts.
Comparisons between gene sets*
overlap between
gene-sets Odds Ratio Chi-Square P Value (1 df)
A. Up-regulated by
IL4 (n = 567) and:
ISGs (n = 370) 30 2.5 23.2 ,0.0001
IRF-1 up-regulated genes (n = 113) 3 0.76 0.209 0.648
Up-regulated by EBV (n = 370) 12 0.94 0.047 0.828
Up- regulated by CD40L/IL4 (n = 370) 42 3.8 66.8 ,0.0001
Down-regulated by EBV (n = 370) 35 3.0 38.7 ,0.0001
Down- regulated by CD40L/IL4 (n = 263) 17 2.0 6.90 0.009
Differentially expressed between EBV and
CD40L/IL4 blasts (n = 249)
34 4.6 75 ,0.0001
Higher in EBV blasts than CD40L/IL4 blasts
(n = 134)
7 1.5 1.22 0.269
Lower in EBV blasts than CD40L/IL4 blasts
(n = 115)
27 8.9 134 ,0.0001
B. Down-regulated by
IL4 (n = 452) and:
ISGs (n = 370) 111 19.6 998 ,0.0001
IRF-1 up-regulated genes (n = 113) 66 57.7 1271 ,0.0001
Up-regulated by EBV (n = 370) 60 7.7 244 ,0.0001
Up- regulated by CD40L/IL4 (n = 370) 27 2.9 27.8 ,0.0001
Down-regulated by EBV (n = 370) 26 2.8 24.6 ,0.0001
Down- regulated by CD40L/IL4 (n = 263) 29 4.6 65.4 ,0.0001
Differentially expressed between EBV and
CD40L/IL4 blasts (n = 249)
49 9.6 259 ,0.0001
Higher in EBV blasts than CD40L/IL4 blasts
(n = 134)
44 19.0 441 ,0.0001
Lower in EBV blasts than CD40L/IL4 blasts
(n = 115)
5 1.6 1.06 0.303
*Numbers in parentheses indicate the number of genes within the gene-set analyzed. Comparisons were restricted to the 16420 genes present on both the HuExon 1.0
ST and the U133 plus2 Affymetrix array platforms. The IL-4 regulated genes were identified experimentally by Elo et al who arrayed IL-2 stimulated T cells treated with or
without IL-4 [35]. Complete gene-lists are available in Data-File S2.
doi:10.1371/journal.pone.0064868.t004
EBV Targeting ISG/IL-4 Pathways for Transformation
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e64868
EBV to growth-transform resting B cells. Standard growth-
transformation assays were therefore set up in which purified B
cells infected in the absence or presence of IL-4 over a range of
EBV doses. Replicate experiments with B cells from three separate
donors (Figure 4) revealed the dose of virus required for 50%
transforming wells to be 23.863.2 (mean m.o.i. 6S.D.) for control
EBV infections, and 56.5 610.2 for EBV plus IL-4. This
represents a 2.4-fold reduction of transforming efficiency by
EBV in the presence of IL-4 (p = 0.0076; paired t-test).
Discordant regulation of IL-4 pathway genes and
malignant transformation by EBV
We and others have previously shown that the transcriptomes of
EBV-transformed LCL and the malignant Hodgkin and Reed-
Sternberg cells (HRS) cells of HL show remarkable similarities
[36,37]. We therefore asked whether the discordant regulation of
genes intersecting the IFN and IL-4 response pathways in EBV-
infected B cells might also be relevant to malignant transformation
in HL. As the normal counterparts of the malignant HRS cells of
HL are germinal center (GC) B cells, we first determined whether
the EBV/ISG/IL-4 associations could also be demonstrated in a
GC B cell model of EBV infection in vitro. To this end, we reprised
our comparisons on a previous array experiment [37] in which we
had profiled germinal center (GC) B cells six weeks following their
infection with EBV to yield lymphoblastoid cell lines (GC-LCLs).
Consistent with our comparison of EBV and CD40L/IL-4
stimulated blasts at day 7, we found that genes up-regulated by
EBV in GC-LCLs were significantly and substantially enriched for
those down-regulated by IL-4 in T cells (OR=12.0, x21 df = 586,
1df p,0.0001; Table 5).
Figure 3. Effect of IL4 on transcription in B cells. Quantitative RT-qPCR assays for selected cellular gene transcripts in peripheral blood B cell
cultures in normal medium or containing IL-4 (assayed at 6 hrs), or infected with EBV in normal medium or containing IL-4 (assayed at 7 days). The
results are expressed as mean 6 SEM of three replicate experiments using B cells from different donors. An established LCL was used as a reference
for all assays, and all values are shown relative to LCL transcript expression= 1, except for SPINT2 and DUSP6 whose expression in the reference LCL
was extremely low (ddCt,12) and where expression is shown relative to control B cell cultures. The six cellular genes shown in (A) were reported by
Elo et al [35] to be down-regulated by IL4 in T cells, whilst the 2 genes shown in (B) were reported to be up-regulated by IL-4 in T cells.
doi:10.1371/journal.pone.0064868.g003
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The transcriptional profile induced by EBV in the GC-LCL
model, which we have just described, was shown previously to
overlap that of HRS cells micro-dissected from biopsies of HL
[37,38]. Therefore, we next examined the overlap between IL-4
transcriptional targets and genes found to be differentially
expressed in micro-dissected HRS cells from 12 cHL when
compared with non-malignant GC centrocytes isolated from
tonsillar lymphocytes by fluorescence activated cell sorting. We
found that genes up-regulated in micro-dissected HRS cells were
enriched for genes which were down-regulated by IL-4 in T cells
(OR=13.8, x21 df = 724, 1df p,0.0001; Table 6).
We hypothesized that if those EBV-induced ISGs which
intersected the IL-4 signaling response and were discordantly
regulated by EBV and IL-4, were to contribute to the process of
transformation in HL, then genes that were up-regulated in micro-
dissected HRS cells would be enriched for genes which were also
up-regulated in EBV infected GC B cells but down-regulated in
IL-4 treated CD4 T cells. Consistent with this hypothesis, we
found that the odds of a gene up-regulated in GC-LCL cells also
being up-regulated in HRS cells were almost 5 times greater
(OR=4.9; 95% CI= 2.9 to 8.5) when that gene was also down-
regulated by IL-4 in T cells compared to when it was not (Figure 5).
By way of a sensitivity analysis, we repeated the above analysis but
this time using the transcriptional profiles generated by a recently
published comparison of EBV-positive and EBV-negative micro-
dissected HRS cells with micro-dissected GC cells from reactive
lymph node sections [39]. Although attenuated, the point estimate
of association remained significant and the 95% confidence
intervals around the estimates generated by these comparisons
all overlapped (Figures S1 and S2). Notably, comparison of EBV-
positive and EBV-negative HRS tumors with normal GC cells
gave essentially similar results (OR=1.9, 95% CI= 1.1–3.4 for
EBV-positive HRS; OR=2.4, 95% CI= 1.4–4.3 for EBV-
negative HRS).
Interestingly, no such correlation was observed when analyzing
the transcriptomes of EBV-positive African endemic Burkitt
lymphoma (eBL) samples arrayed by Piccaluga et al [40]; as
shown in Figure S3, the odds of a gene up-regulated in GC-LCL
cells also being up-regulated in eBL tumors were the same whether
or not that gene was also down-regulated by IL-4 in T cells
(OR=1.0; 95% CI=0.5 to 1.9).
EBV-positive cases of HL show a Latency II pattern of gene
expression, in which LMP1 and LMP2 are expressed in addition
to the EBNA1, EBERS, and viral miRNAs that are expressed in
eBL tumors showing a Latency I pattern of viral gene expression.
We therefore anticipated that those genes which were up-regulated
both in HRS relative to GC-centrocytes and in EBV-transformed
LCL relative to uninfected GC-B cells but down-regulated by IL-4
in T cells, might be enriched for genes known to be transcriptional
targets of LMP1 or LMP2A. We identified a total of 92 signature
genes fulfilling these HRS/EBV/IL-4 criteria (Table S2), and
comparison with our previously published array datasets [41,42]
showed that 29/92 (32%) of these genes were indeed up-regulated
by LMP1 (26 genes) or by LMP2A (5 genes) or by both (2 genes) in
GC-B cells (Table 7).
Discussion
This study on the transcriptional programs of EBV infected B
cells and CD40L/IL-4 stimulated B cells has identified a critical
set of genes at the intersection of the IFN and IL-4 signaling
pathways that modulate the transforming functions of EBV.
Although the transcriptomes of EBV and CD40L/IL-4 blasts
showed substantial overlap, reflecting common proliferation and
apoptosis related pathways, the expression of 255 genes was found
to differ significantly between the two types of blasts (p,0.01;
FC.2). Initial gene ontology analysis indicated that this set of 255
Figure 4. Effect of IL4 on EBV-induced B cell transformation.
Purified B cells were infected with EBV at a series of multiplicities of
infection (m.o.i.) in the absence or presence of added IL-4. For each
infection dose, 103 B cells were seeded into each of the 96-wells of a
microtest plate. The cultures were maintained in the presence or
absence of IL-4 for 6 weeks, at which point the number of wells
containing viable transformed colonies was counted. The data points
and error bars represent the mean 6 s.d for replicate experiments
performed on B cells from three separate donors. Transformation
efficiency, defined as the M.O.I. at which 50% of the cultures were
transformed, was 23.863.2 for EBV alone and 56.5610.2 for EBV plus IL-
4.
doi:10.1371/journal.pone.0064868.g004
Table 5. Expression of IL-4 regulated genes in GC-B cell LCL.
Comparisons between gene sets*
overlap between
gene-sets Odds Ratio Chi-Square P Value (1 df)
A. Down-regulated by IL-4 (n = 484) and: Up-regulated by EBV (n = 484) 92 12.0 586 ,0.0001
Down- regulated by EBV (n = 484) 42 4.3 85.4 ,0.0001
B. Up-regulated by IL-4 (n = 640) and: Up-regulated by EBV (n = 640) 51 2.9 50.9 ,0.0001
Down- regulated by EBV (n = 640) 52 3.0 54.2 ,0.0001
*Numbers in parentheses indicate the number of genes within the gene-set analyzed.
Of the 21014 annotated genes in the U133 plus2 Affymetrix array platform, 484 were identified experimentally by Elo et al [35] as being down-regulated and 640 up-
regulated by IL-4 in T cells. Gene-sets up- or down-regulated in EBV-transformed LCL from GC-B cells relative to uninfected GC-B cells were identified by Leonard et al
[37]. For the determination of OR and statistical significance, equal sized probe-sets were compared by ranking probe-sets according to the magnitude of FC of the GCB-
LCL relative to uninfected GC-B cells, and selecting the top 484 or 640 unique genes. Complete gene-lists are available in Data-File S2.
doi:10.1371/journal.pone.0064868.t005
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genes was substantially enriched for genes involved in innate
cellular responses to viral infection, most notably ISGs. At first
glance, this enrichment might seem an entirely predictable
consequence of the innate responses to a viral infection, which
results in activation of IFN pathways aimed at preventing viral
genome replication, inhibiting cell proliferation and/or inducing
cell death. However, EBV infected cells are not growth-inhibited
or dying any more so than CD40L/IL-4 stimulated cells.
Upon infection of cells by viruses, the ISGs are regulated in
response to ligation of pattern recognition receptors (PRRs),
including Toll-like receptor family members recognising virion
glycoproteins or DNA/RNA [43]. EBV has the potential to
activate several PRRs, including TLR3 and TLR7 [44,45], and a
role for viral RNAs, most notably the EBERs, in triggering IFN
production and IFN responses is well-established [46,47]. As with
other viruses, EBV has to modulate these innate intracellular
responses in order to successfully infect and persist in the cells. The
prevailing evidence suggests that EBV not only evades the
intended consequences of innate intracellular responses, but
actually subverts them to facilitate growth-transformation
[44,48,49]. Consistent with this property of EBV, co-stimulation
of TLR9 with the CpG synthetic ligand during EBV infection of B
Table 6. Expression of IL-4 regulated genes in HRS malignant cells.
Comparisons between gene sets* overlap between gene-sets Odds Ratio Chi-Square P Value (1 df)
A. Down-regulated by IL-4 (n = 484) and: Up-regulated in HRS (n = 484) 101 13.8 724 ,0.0001
Down- regulated in HRS (n = 484) 19 1.8 5.53 0.019
B. Up-regulated by IL-4 (n = 640) and: Up-regulated in HRS (n = 640) 56 3.2 68.4 ,0.0001
Down- regulated in HRS (n = 640) 57 3.0 59.5 ,0.0001
*Numbers in parentheses indicate the number of genes within the gene-set analyzed.
IL-4-regulated genes were identified experimentally by Elo et al [35]; of the 21014 annotated genes in the U133 plus2 Affymetrix array platform, 640 were identified as
being up-regulated and 484 down-regulated by IL4 in T cells. Genes that were up- or down-regulated in microdissected HRS malignant cells from HL biopsies relative to
control GC-centrocytes were identified from the data of Brune et al [38]. Complete gene-lists are available in Data-File S2. For the determination of OR and statistical
significance, equal sized gene-sets were compared by ranking probe-sets according to the magnitude of FC of the HRS cells, and selecting the top 640 or 484 unique
genes.
doi:10.1371/journal.pone.0064868.t006
Figure 5. Discordant expression of IL-4 regulated transcripts by EBV and in malignant HRS cells. Gene-sets regulated by IL-4, in EBV-
infected GC B cells, and in micro-dissected HRS cells were identified as described in Tables 5 and 6. To facilitate analysis of statistical significance,
equal sized gene-sets were compared by ranking probe-sets according to the magnitude of FC of the HRS cells, and selecting the top 640 or 484
unique genes. Complete gene-lists are available in Data-File S2.
doi:10.1371/journal.pone.0064868.g005
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cells in vitro, actually enhances LCL outgrowth [48,49]. There are
likely to be several molecular mechanisms by which EBV utilizes
the pro-proliferative effects of TLR and IFN signaling whilst
avoiding the anti-viral end-points of growth-inhibition and
apoptosis. One intriguing example identified by Martin et al
[44] was the induction of alternatively-spliced IRF-5 transcripts
that inhibit the anti-proliferative effects of the regular IRF-5
isoform. Another novel possibility is suggested from our analysis of
the ISGs that are differentially expressed between EBV blasts and
CD40L/IL4 blasts (Table 3). Although only 6 ISGs were
expressed at significantly lower levels in EBV blasts, one of these
was RNF19B (expressed 2.9x lower in EBV blasts; p = 0.0012), a
E3 ubiquitin-protein ligase that targets substrates such as UCKL1
for degradation; UCKL1 is a uridine kinase/uracil phosphoribo-
syltransferase that binds to EBV EBNA3A, an interaction that
leads to a nuclear accumulation of UCKL1 that has been
hypothesized to be important for EBV-induced proliferation [50].
The IFN signaling pathway is also a component of the DNA
damage response (DDR) that is triggered following EBV-induced
proliferation of infected B cells [51,52]. However, it is unlikely that
the DDR is responsible for the predominance of ISGs amongst
those genes differentially expressed between EBV and CD40L/IL-
4 blasts. Indeed, whilst we confirmed the observation of Nikitin et
al who identified 20 DDR genes that were transcriptionally up-
regulated following EBV infection [52], we also found that only
one of these genes (POLQ) was expressed in CD40L/IL-4 blasts at
a significantly lower level (2.7-fold; p = 0.009) than in EBV blasts.
It should be noted that whilst the genes differentially expressed
by EBV and CD40L/IL-4 blasts were enriched for ISGs, a larger
proportion of ISGs (58/370) was commonly regulated by both
EBV and CD40L/IL-4. This begs the question, as to why some
ISGs are differentially regulated between the two types of blasts
and others concordantly regulated. Strikingly, we found that genes
that were expressed at significantly greater levels in EBV blasts
than in CD40L/IL-4 blasts were substantially and significantly
Table 7. Regulation by LMP1 and LMP2A of EBV/HRS/IL-4 signature genes.
Category Gene Symbol Ontology
Genes up-regulated by LMP1 : ATF3 transcription
CCR7 motility, signaling
CD274 signaling
CD97 signaling, adhesion
CFLAR apoptosis
DUSP4 signaling
ETV6 transcription,
IL6R motility, apoptosis, signaling
IRF2BP2 transcription
LACTB -
LAMP3 proliferation
LITAF apoptosis, transcription
MAFF transcription, differentiation
MIR155HG miRNA
MYC proliferation, apoptosis
PAM protein-modification
PERP apoptosis
RHEBL1 signaling
SLAMF1 proliferation, apoptosis
SNX9 intracellular trafficking
SOCS2 apoptosis, signaling
SRGN motility, apoptosis
TRAF1 apoptosis, signaling
ZBTB32 transcription, DNA-repair
Genes up-regulated by both LMP1 and LMP2A : BHLHE40 transcription
SLAMF7 adhesion, apoptosis
Genes up-regulated by LMP2A : CCL3 motility, signaling
CCL4 motility, adhesion, signaling
GNPDA1 catabolic
The EBV/HRS/IL-4 signature was defined as the 92 genes that were identified as common to the 2084 genes up-regulated in EBV-transformed LCLs established from GC-
B cells [37], the 1747 genes up-regulated in HRS [38], and the 484 genes down-regulated by IL4 in T cells [35]. These 92 genes were then compared to those identified as
up-regulated following expression of LMP1 or LMP2A in GC-B cells [41,42]. All arrays were performed on the U133 plus2 Affymetrix array platform, where the probe-sets
corresponded to 21014 annotated genes. The Gene Ontology function descriptions were obtained primarily from NCBI and AmiGO databases, assisted by manual
literature search. Complete gene-lists are available in Data-File S2.
doi:10.1371/journal.pone.0064868.t007
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enriched for genes that were down-regulated by IL-4 in other cell
systems. This finding is consistent with the observation that IFNs
and cytokines such as IL-4 are known to cross-regulate each
other’s signaling in different cell types, including B cells [32–35].
We were able to confirm in many cases that the induction by EBV
of those ISGs that were differentially expressed in EBV blasts was
reduced following infection in the presence of IL-4 (Figure 3).
Furthermore, this effect of IL-4 was correlated with a significant
impairment of transformation efficiency (Figure 4).
The results of these experiments are also consistent with the
observation that while IL-4 can act as a potent co-stimulus for
proliferation survival and differentiation in both B and T
lymphocytes, hence its widespread experimental use in generating
B cell blasts, it also has a modest inhibitory effect on proliferation
and induces apoptosis most notably in human B cell neoplasms,
and in some non-hematopoietic malignant cells [3–10]. They also
suggest that where EBV and IL4 impact on common signaling
pathways, for example, the induction of this subset of ISG, the
EBV transcriptional program must prevail for transformation to
occur.
It should be added that the importance of IL-4 response genes
may not be confined to the ISGs that are induced by EBV; the
smaller set of genes that are down-regulated by EBV but
maintained or up-regulated by IL-4 includes two, SPINT2
[53,54] and DUSP6 [55–57], that have been identified as
candidate tumor-suppressor genes in non-hematopoietic cancers.
It should be emphasized that the definition of a tumor suppressor
gene is dependent upon cell context, and that whilst DUSP6 has
been widely reported as having tumor suppressor function, there
are reports in other cell models describing DUSP6 as an oncogene
[58,59]. Although we are unaware of any published evidence
implicating DUSP6 or SPINT2 as tumor suppressors in B
lymphoid malignancies, their expression was found to be increased
in our experiments where IL-4 impaired EBV-induced transfor-
mation (Figures 3B, 4).
The observation that many of the transformation-associated
ISGs which we have identified are overexpressed in the malignant
HRS cells of HL (Figure 5, Table 6), and that a substantial number
of these are also concordantly up-regulated by LMP1 or LMP2A
in normal GC B cells (Table 7), suggests this maybe a profitable
line of inquiry. Although IL-4 is not usually expressed in HL [60–
62], IL13 with which it shares functional receptors [63,64] and
remarkably similar biological functions is expressed [65]. Further-
more, proliferation of HL-derived lines in vitro and in vivo is reduced
by antibodies to IL-13 or by decoy receptor molecules, suggesting
that IL-13 can act as an autocrine growth-factor in HL [66,67].
Activated STAT6, which is an essential mediator of many IL-4/
IL-13-regulated genes [35] is usually detected in HL along with
activated STAT3 [66]. However, IFN can inhibit activation of
STAT6 by cytokines [68] and is also expressed by the HRS cells of
HL [69]. Furthermore, IL-13 in the lesions of EBV-positive cases
of HL would be expected to induce and maintain the high levels of
LMP1 expression in the absence of EBNA2 in these tumors [70],
which in turn would stimulate expression of ISGs [44]. Therefore,
extrapolating from our in vitro transformation experiments
(Figures 3, 4), we suggest that the pathogenesis of HL is a
consequence in part of competing and conflicting influences on
genes which are at the intersection of the IFN and IL-4/IL-13
pathways, and whose dysregulation is necessary for cellular
transformation.
Although the inferences we draw concerning the over-repre-
sentation of ISG among genes found to be up-regulated in micro-
dissected HRS cells were first predicated on an array experiment
in which the EBV status of the tumors contributing to the analysis
are not reported [38], we might reasonably expect 40–60% of
these tumors to have had EBV in their malignant cells.
Furthermore, a recent study by Steidl et al [39], who arrayed
micro-dissected HRS cells from 7 EBV-positive and 17 EBV-
negative classical HL samples, indicated a remarkable similarity in
their transcriptomes; only 56 probe-sets corresponding to just 46
annotated genes were differentially expressed between the EBV-
positive and –negative tumors (.2FC, p,0.01; taken from the
supplementary information of the Steidl paper). This in no way
undermines our conclusions, rather it adds to the body of evidence
that EBV infection is but one route to the development of this
tumor. For example, a major signaling function of LMP1 is to
constitutively activate NF-kB [71–73] and many EBV-negative
cases of HL carry mutations of NF-kB pathway genes that effect
the same result [74,75].
We therefore propose that the regulation by EBV of genes at the
intersection of IFN and IL-4 pathways that occurs early following
infection of B cells has relevance to the development or
maintenance of an EBV-associated malignancy, Hodgkin’s lym-
phoma.
Supporting Information
Data-File S1 Probe-lists from arrays of EBV-infection
and CD40L/IL-4 stimulation of primary B cells, and
results of DAVID gene-ontology analysis.
(XLSX)
Data-File S2 Gene-lists used for the analyses reported
in Figures 1,3, and 5; Tables 1 and 3, 4, 5, 6, 7; and
Figures S1, S2, S3.
(XLSX)
Figure S1 Discordant expression of IL-4 regulated
transcripts by EBV and in malignant EBV-positive
micro-dissected HRS cells. Analysis of gene-sets was per-
formed as in Figure 5 except that the genes regulated in HRS cells
were determined from the array data of Steidl et al [39], comparing
the genes expressed in micro-dissected HRS cells from 7 EBV-
positive HL tumors with those expressed in micro-dissected GC
cells from 5 normal reactive lymph-nodes. To facilitate analysis of
statistical significance, equal sized probe-sets were compared by
ranking probe-sets according to the magnitude of FC of the HRS
cells, and selecting the top 640 or 484 unique genes. Complete
gene-lists are available in Data-File S2.
(TIF)
Figure S2 Discordant expression of IL-4 regulated
transcripts by EBV and in malignant EBV-negative
micro-dissected HRS cells. Analysis of gene-sets was per-
formed as in Figure 5 except that the genes regulated in HRS cells
were determined from the array data of Steidl et al [39], comparing
the genes expressed in micro-dissected HRS cells from 17 EBV-
negative HL tumors with those expressed in micro-dissected GC
cells from 5 normal reactive lymph-nodes. To facilitate analysis of
statistical significance, equal sized probe-sets were compared by
ranking probe-sets according to the magnitude of FC of the HRS
cells, and selecting the top 640 or 484 unique genes. Complete
gene-lists are available in Data-File S2.
(TIF)
Figure S3 Discordant expression of IL-4 regulated
transcripts by EBV and in malignant eBL tumors.
Analysis of gene-sets was performed as in Figure 5 except that
the genes regulated in eBL tumors were determined from the array
data of Piccaluga et al [40], comparing the genes expressed in 9
African EBV-positive eBL tumors with those expressed in 5
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samples of normal GC centroblasts. To facilitate analysis of
statistical significance, equal sized probe-sets were compared by
ranking probe-sets according to the magnitude of FC of the HRS
cells, and selecting the top 640 or 484 unique genes. Complete
gene-lists are available in Data-File S2.
(TIF)
Table S1 Validation of RT-qPCR assays on 40 genes
from the set of 255 genes identified in microarrays as
significantly altered between EBV blasts and CD40L/IL-
4 blasts.
(DOCX)
Table S2 List of 92 signature genes expressed more
highly in HRS cells than in normal centrocytes, and up-
regulated by EBV infection of GC B cells, and also down-
regulated by IL-4 in T cells.
(DOCX)
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